Professor Richard Martin
B.Med.Sci., B.M.,B.S.(Nott.), M.Sc.(Lond.), M.R.C.G.P., PhD
Current positions
- Associate Pro Vice Chancellor (Research & Innovation) & Professor of Clinical EpidemiologyBristol Medical School (PHS)
Contact
Press and media
Many of our academics speak to the media as experts in their field of research. If you are a journalist, please contact the University’s Media and PR Team:
Research interests
My current principal areas of research are: i) prostate cancer aetiology (with a focus on metabolic factors such as the IGF system), predicting its progression and secondary and tertiary prevention of the disease via population-based screening and low-toxicity nutritional and lifestyle interventions; ii) the short- and long-term child and adult health effects of breastfeeding and early growth; and iii) uncovering unexpected beneficial and adverse effects of commonly prescribed drugs through pharmaco-epidemiological studies based on automated clinical databases such as the UK GPRD. I am lead principal investigator (with Jenny Donovan, Freddie Hamdy and David Neal) on a population-based cluster randomised controlled trial of PSA testing for prostate cancer (the CAP trial) that involves over 410,000 UK men and co-principal investigator (with Mike Kramer and Emily Oken) on the long-term follow-up of a cluster randomised controlled trial of a breastfeeding promotion intervention that involves over 17,000 children in the Republic of Belarus (the PROBIT trial). I am lead principal investigator (with Professor Caroline Relton) on a £4.1 million CRUK programme grant in Integrative Cancer Epidemiology, combining genetic, metabolomic and epigenetic technologies to understand causal risk factors, mechanistic targets and predictive biomarkers in a variety of cancers. In was co-PI with Dr Sarah Lewis on the WCRF funded project to develop systematic review methodology for mechanistic studies. I lead a cancer work-stream within the Bristol NIHR Biomedical Research Centre. I am interested in robustly assessing the causality of observational associations using instrumental variables analysis, working in collaboration with Frank Windmeijer, George Davey Smith, Tom Palmer and Neil Davies. With Willie Hamilton, Mike Stevens, Rachel Dommet and Theresa Redaniel, I have a developing interest in the presentation and diagnosis of childhood, teenage and young adult cancers in primary care.
Projects and supervisions
Research projects
- BRC2 - Diet and Physical Activity Theme- Principal Investigator- Managing organisational unitBristol Medical School (PHS)- Dates- 01/12/2022 to 30/11/2027 
- 8074 (C18281/A29019) ICEP2 - Programme Award: Towards improved casual evidence and enhanced prediction of cancer risk and survival- Principal Investigator- Managing organisational unitBristol Medical School (PHS)- Dates- 01/10/2020 to 30/09/2025 
- MRC (EBI) Proximity to Discovery Award - Venexia Walker- Principal Investigator- Managing organisational unitBristol Medical School (PHS)- Dates- 01/03/2017 to 31/08/2017 
- Costs for Richard Martin (Cranfield University)- Principal Investigator- Managing organisational unitBristol Medical School (PHS)- Dates- 01/09/2013 to 01/09/2016 
- IEU - UWA 2- Principal Investigator- Managing organisational unitBristol Medical School (PHS)- Dates- 01/06/2013 to 31/03/2018 
Publications
Recent publications
09/04/2025Cluster randomised triAl of PSA testing for Prostate cancer (CAP) Study, longer term (18- and 20-year) follow up: Version 1.0 8th April 2025
A proteogenomic analysis of the adiposity colorectal cancer relationship identifies GREM1 as a probable mediator
International Journal of Epidemiology
Cardiovascular risk associated with carotid bifurcation plaques producing <50% stenosis and its modulation by presence of common femoral plaques
Vascular Medicine
Epigenetic markers of adverse lifestyle identified among evening and night shift workers in two UK population-based studies
Chronobiology International - The Journal of Biological and Medical Rhythm Research
Integrating single-cell transcriptome-wide Mendelian randomization and differentially expressed gene analyses to prioritise dynamic immune-related drug targets for cancers
Advanced Science




